Indicación
Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg. Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.
En otros países
Los mismos principios activos en otros registros, empezando por la misma marca.
Fichas nacionales
Los registros nacionales en los que figura este medicamento de la UE.